Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-01-2015 | Original Article

⁶⁸Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to ¹²³I-MIBG SPECT/CT

Authors: Alexander Kroiss, Barry Lynn Shulkin, Christian Uprimny, Andreas Frech, Rudolf Wolfgang Gasser, Christoph Url, Kurt Gautsch, Ruth Madleitner, Bernhard Nilica, Georg Mathias Sprinzl, Guenther Gastl, Gustav Fraedrich, Irene Johanna Virgolini

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2015

Abstract

Purpose

The aim of this study was to compare the accuracy of ¹²³I-MIBG SPECT/CT with that of ⁶⁸Ga-DOTATOC PET/CT for staging extraadrenal paragangliomas (PGL) using both functional and anatomical images (i.e. combined cross-sectional imaging) as the reference standards.

Methods

The study included three men and seven women (age range 26 to 73 years) with anatomical and/or histologically proven disease. Three patients had either metastatic head and neck PGL (HNPGL) or multifocal extraadrenal PGL, and seven patients had nonmetastatic extraadrenal disease. Comparative evaluation included morphological imaging with CT, functional imaging with ⁶⁸Ga-DOTATOC PET, and ¹²³I-MIBG imaging. The imaging results were analysed on a per-patient and on a per-lesion basis.

Results

On a per-patient basis, the detection rate of ⁶⁸Ga-DOTATOC PET was 100 %, whereas that of planar ¹²³I-MIBG imaging was 10.0 % and with SPECT/CT 20.0 % for both nonmetastatic and metastatic/multifocal extraadrenal PGL. On a per-lesion basis, the overall sensitivity of ⁶⁸Ga-DOTATOC PET was 100 % (McNemar p < 0.5), that of planar ¹²³I-MIBG imaging was 3.4 % (McNemar p < 0.001) and that of SPECT/CT was 6.9 % (McNemar p < 0.001). Both ⁶⁸Ga-DOTATOC PET and anatomical imaging identified 27 lesions. Planar ¹²³I-MIBG imaging identified only one lesion, and SPECT/CT two lesions. Two additional lesions were detected by ⁶⁸Ga-DOTATOC PET but not by either ¹²³I-MIBG or CT imaging.

Conclusion

Our analysis in this patient cohort indicated that ⁶⁸Ga-DOTATOC PET/CT is superior to ¹²³I-MIBG SPECT/CT, particularly in head and neck and bone lesions, and provides valuable information for staging extraadrenal PGL, particularly in patients with surgically inoperable tumours or multifocal/malignant disease.

Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94:4757–67.PubMedCentralPubMedCrossRef

Maurea S, Cuocolo A, Reynolds JC, Neumann RD, Salvatore M. Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison. Q J Nucl Med. 1996;40:365–71.PubMed

Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullaart RP. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med. 2008;49:1232–7.PubMedCrossRef

Rufini V, Treglia G, Castaldi P, Perotti G, Giordano A. Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma: a systematic review. Q J Nucl Med Mol Imaging. 2013;57:122–33.PubMed

Blanchet EM, Martucci V, Pacak K. Pheochromocytoma and paraganglioma: current functional and future molecular imaging. Front Oncol. 2012;1:58.PubMedCentralPubMedCrossRef

Taïeb D, Neumann H, Rubello D, Al-Nahhas A, Guillet B, Hindié E. Modern nuclear imaging for paragangliomas: beyond SPECT. J Nucl Med. 2012;53:264–74.PubMedCrossRef

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–18.PubMedCrossRef

Taïeb D, Timmers HJ, Hindié E, Guillet BA, Neumann HP, Walz MK, et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012;39:1977–95.PubMedCrossRef

Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazúrová I, et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49:1613–9.PubMedCentralPubMedCrossRef

10.

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2000;284:3043–5.

11.

Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:2436–46.PubMedCrossRef

12.

Decristoforo C, Knopp R, von Guggenberg E, Rupprich M, Dreger T, Hess A, et al. A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun. 2007;28:870–5.PubMedCrossRef

13.

Timmers HJ, Taieb D, Pacak K. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm Metab Res. 2012;44:367–72.PubMedCrossRef

14.

Tischler AS. Pheochromocytoma: time to stamp out "malignancy"? Endocr Pathol. 2008;19:207–8.PubMedCrossRef

15.

Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther. 2001;91:35–62.PubMedCrossRef

16.

King KS, Chen CC, Alexopoulos DK, Whatley MA, Reynolds JC, Patronas N, et al. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011;96:2779–85.PubMedCentralPubMedCrossRef

17.

Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95:2800–10.PubMedCrossRef

18.

Maurice JB, Troke R, Win Z, Ramachandran R, Al-Nahhas A, Naji M, et al. A comparison of the performance of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012;39:1266–70.PubMedCrossRef

19.

Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38:865–73.PubMedCrossRef

20.

Sharma P, Thakar A, Suman KC, Dhull VS, Singh H, Naswa N, et al. 68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma. J Nucl Med. 2013;54:841–7.PubMedCrossRef

21.

Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, et al. A retrospective comparison between (68)Ga-DOTA-TOC PET/CT and (18)F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging. 2013;40:1800–8.PubMedCrossRef

Title: 68Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to 123I-MIBG SPECT/CT
Authors: Alexander Kroiss
Barry Lynn Shulkin
Christian Uprimny
Andreas Frech
Rudolf Wolfgang Gasser
Christoph Url
Kurt Gautsch
Ruth Madleitner
Bernhard Nilica
Georg Mathias Sprinzl
Guenther Gastl
Gustav Fraedrich
Irene Johanna Virgolini
Publication date: 01-01-2015
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2892-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

⁶⁸Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to ¹²³I-MIBG SPECT/CT

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment

177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study

68Ga-DOTA0-Tyr3-octreotide positron emission tomography in nasopharyngeal carcinoma

Test–retest reliability of 11C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain

Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside

Diagnostic accuracy and impact on management of 18F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review